

June 14, 2018



# Kane Biotech to Present at The MicroCap Conference in Toronto

## Conference Held June 21 Featuring Attractive Companies Across All Sectors

WINNIPEG, Manitoba, June 14, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the "Corporation" or "Kane Biotech") is pleased to announce that it will present at The MicroCap Conference being held in Toronto on June 21, 2018. Mark Ahrens-Townsend, President & CEO of Kane Biotech, will be giving a presentation and meeting with investors attending the conference.

Event: The MicroCap Conference  
Date: Thursday, June 21, 2018  
Time: 11:30 AM to 11:55 AM Local Time  
Location: Sheraton Centre, Toronto,  
Canada

Investors interested in meeting with Kane Biotech should contact Tirth Patel, VP Investor Relations at [tpatel@edisongroup.com](mailto:tpatel@edisongroup.com).

### About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Corporation has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane™ are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol "KNBIF."

**For more information, please visit [www.kanebiotech.com](http://www.kanebiotech.com) or contact:**

Mark Ahrens-Townsend  
President & CEO  
Kane Biotech Inc.  
+1 (204) 477-7592  
[ir@kanebiotech.com](mailto:ir@kanebiotech.com)

Tirth Patel  
Vice President - Investor Relations  
Edison Advisors

+1 (646) 653-7035

[tpatel@edisongroup.com](mailto:tpatel@edisongroup.com)

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*



Source: Kane Biotech Inc.